Antifibrotic Activity of Bevacizumab on Human Tenon's Fibroblasts In Vitro

Abstract

Bevacizumab disrupted fibroblast proliferation, inhibited collagen gel contraction ability, and induced fibroblast cell death at concentrations greater than 7.5 mg/mL in serum-free conditions. These results demonstrated that bevacizumab inhibited a number of fibrosis activities in culture. These activities may underpin the antifibrosis effect proposed in vivo.

Short-term Results of Trabeculectomy Using Adjunctive Intracameral Bevacizumab

“…25,26 Second, there are evidences of direct effect of VEGF on fibroblasts, which if inhibited by anti-VEGF agents, scar formation process could be modulated. [27][28][29][30] The goal of this study was to compare the outcome of primary trabeculectomy in open-angle glaucoma patients with or without adjunctive intracameral bevacizumab. No antifibrotic agents (MMC or 5-FU) were used in our patients.…”

Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study

“…The ability of anti-VEGF agents (such as bevacizumab at a standard 1.25 mg/0.05 mL concentration) to inhibit the proliferation and migration of Tenon fibroblasts has been well documented 7 8. The use of anti-VEGF agents may be particularly interesting in glaucoma patients, since they have increased concentrations of VEGF in the aqueous humour 7 9…”

Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study

“…Vascular endothelial growth factor also affects a fibroblastic activity in addition to angiogenesis [40]. In a study by Evelyn et al, found that bevacizumab disrupted fibroblast proliferation, and the constriction ability of collagen gel was disabled [41].…”